Current cell therapies are slow to manufacture, costly, and limited to specialized centers. In vivo cell therapies could overcome these barriers by programming cells directly inside the body. This can be achieved by delivering the right sequence to the right tissues and cells, with precise targeting and selective translation.
This is the ‘kernal’ of our mRNA therapeutics platform.
Our therapeutics are delivered to target cells and programmed with state-of-the-art AI models to ensure selective translation in these cells — enabling scalable in vivo CAR-T therapies for patients with cancer and auto-immune diseases.
See how it works